natgillin/translations-raw huggingface dataset:
Space group: P21212 Molecules of Compound (I)/asymmetric unit: 1 
Prostorna grupa: P2,212 Molekule spoja (T)/asimetrična jedinica: 1
Average of 3 batches 
Prosjek od 3 pokušaja
For years monoamine reuptake inhibition has been studied for treatment of depression, i.e. 
Već se godinama proučava inhibicija reapsorpcije monoamina radi tretmana depresije npr.
They included a clinical assessment of the nails, measuring onychoschizia and ungual brittleness by means of a 5-point semi quantitative scale from 0=none to 4=very severe. 
Uključivali su kliničku procjenu noktiju, mjerenje listanja noktiju i ungualne lomljivosti, pomoću semikvantitativne ljestvice od 5 točaka, od 0 = nije prisutno do 4 = jako ozbiljno.
The effect of heating is also particularly dangerous, so that also distillation—while permitting to discard the lower boiling and higher boiling fractions from the oily matrix—induces by itself a high degradation and forming of polymeric residues. 
Učinak zagrijavanja je također naročito opasan, tako da 1 destilacija - ako se dozvoljava odbacivanje nižih vrijućih i viših vrijućih frakcija iz uljnog matriksa - inducira sama po sebi visoku degradaciju i stvaranje polimernih ostataka.
Options And Alternatives 
Opcije i alternative
which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, -NH2, 
O-Het, koji je opcionalno dalje supstituiran s jednim, dva ili tri supstituenta X, pri čemu je svaki X odabran iz skupine koja se sastoji od sljedećih: halogen, -OH, okso, C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, Hetaril, -NH2,-NH(CH3),
A mobile lifting assembly as claimed in claim 3, further comprising two cradles connected to respective ones of the two pairs of lifting devices. 
Mobilni sklop za podizanje prema patentnom zahtjevu 3 nadalje obuhvaća dvije kolijevke (12) povezane s odgovarajuća dva para (8, 10) naprava za podizanje (6).
Aaa is an amino acid residue selected from Ser, Asn and Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified; 
Aaa je aminokiselinski ostatak, kojeg se bira između Ser, Asn i Thr; gdje je njegov C-kraj slobodni kraj, amidiran ili esterificiran;
The method according to claim 16, wherein said flat surface or shape is made of rigid materials which are resistant to temperature and pressure, a shape having small cavities which are complementary, at the overlaps of the elements, with respect to the differences in thicknesses or the stitched seams of the upper, to provide the inner surface of the upper, having a pressing surface of the membrane, that is flat. 
Postupak u skladu s patentnim zahtjevom 17, naznačen time, da kada su navedena ravna površina ili oblik (20) izrađeni od krutih materijala koji su otporni na temperaturu i tlak, navedeni oblik ima male šupljine (20a), koje su komplementarne, na preklapanjima elemenata s obzirom na razlike u debljini ili šivane šavove gornjišta (12) tako da je unutarnja površina gornjišta (12), to jest površina membrane za prešanje, ravna.
∘ is free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.001 mM. 
ne sadrži aminokiseline ili sadrži jednu 1li više aminokiselina u (zajedničkoj) koncentraciji do najviše 0.1 mM: i
a powder X-ray diffraction spectrum comprising a peak at least at one of the following ° 2θ angles (±0.2): 12.04, 13.68, 17.72 and/or 19.01, as measured with Cu—Ka irradiation (1.54060 Å); 
Rendgenski spektar praha koji sadrži pikove pri slijedećim * 20 uglovima (+ 0.2): 12.04, 13.68, 17.721 19.01, mjereno Cu-Ka. zračenjem (1.54060 A);
The process of claim 1, wherein the opioid analgesic is selected from the group consisting of oxycodone, hydromorphone, hydrocodone, codeine, morphine, buprenorphine, pharmaceutically acceptable salts thereof and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je opioidni analgetik odabran iz skupine koja se sastoji od oksikodona, hidromorfona, hidrokodona, kodeina, morfina, buprenorfina, njihovih farmaceutski prihvatljivih soli i njihovih smjesa.
drying with stirring or granulating every qualified period (e.g. every hour), 
- < sušenje uz miješanje ili granulaciju kroz svaki određeni period (primjerice svaki sat),
reacting compound 4 with a two carbon olefination reagent under olefin forming conditions to form compound 6 
HO" d) Reakciju spoja 4 s dvokarbonskim olefinationskim reagensom pod uvjetima u kojima se tvori olefin za 15 dobivanje spoja 6;
11154-9. A method for treating cancer in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of synthetic 2-acetylnaphtho[2,3-b]furan-4,9-dione, and 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion, a drugi agens je gemcitabin, pri čemu je prvi agens formuliran u sastavu koji sadrži Gelucire&.
R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; 
R-R* nezavisno izabrani iz vodika, C;-alk(en/injil, Cag-cikloalk(enjil i C,.s-cikloalk(enjil-C,-alk(en/injil ili R' i R? zajedno s dušikom tvore 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu, a opcionalno rečeni prsten sadrži, uz dušik, jedan heteroatom izabran iz dušika, kisika ili sumpora;
The composition of claim 3 in a dosage form for oral administration. 
Smjesa iz zahtjeva 3, naznačena time, što je u doznoj formi za oralnu primjenu.
A solution is previously know from EP-A1-1 008 459 in which the data portion produced by laminating plastic material to form a uniform part is attached to the attachment portion utilizing a strip provided with projections. 
Rješenje je od prije poznato iz EP-A 1-1008 459, u kojem rješenju je predio za podatke izrađen pomoću spajanja slojeva plastičnog materijala, da bi se na taj način dobio jednoličan dio koji se spaja s predjelom za povezivanje uz upotrebu trake koja je snabdjevena s izbočenjima.
Oral or inhaled Glucocorticosteroids 
- oralni ili inhalacijski glukokortikosteroidi,
wherein said cyclophosphamide is administered before said antibody or PD-1 binding fragment thereof and said antibody or PD-1 binding fragment thereof is administered without cyclophosphamide following administration of cyclophosphamide; 
pri čemu se navedeni ciklofosfamid se daje prije navedenog fuzijskog proteina i navedeni fuzijski protein se daje bez ciklofosfamida nakon davanja ciklofosfamida;
is a linker L connected to the anti-DLL3 antibody; 
R'" je poveznica spojena na protutijelo anti-DLL3;
the second fragment comprises a second proximal end within a second repeat portion; and wherein the first fragment and the second fragment are adjacent to one another and wherein the first repeat portion and the second repeat portion have sequence similarity to one another. The term polypeptide refers to a contiguous sequence of amino acids. 
(iv) drugi fragment ima drugi proksimalni kraj; i gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
(xvii) the lysine at position 11 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, D, E, G, H, L, M, N, P, Q, R, S, T, and V. 
tirozin na položaju 11 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V ili W.
adjusting the solution resulting from step (viii) to a protein concentration of 5 to 7% and a pH value of 5.5 to 7. 
(ix) podešavanje otopine dobivene u koraku (viii) do koncentracije proteina od 5 do 7% 1 pH vrijednosti od 5.5 do
The method of claim 1, wherein said connecting page has a thickness comprised in a range of about 0.2 mm-0.5 mm. The method of claim 1, wherein said electronic data storage means is an RFID element. 
Identifikacijski dokument (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je debljina navedene spojne stranice (402) u rasponu od oko 0,2 - 0,5 mm.
concomitantly or in sequence, of a therapeutically effective amount of a compound of the invention and one or more further drug substances, said further drug substance being useful in any of the particular indications set forth hereinbefore; 
Kombinacija, naznačena time, da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 3, te jednu ili više drugih ljekovitih tvari, pri čemu je spomenuta druga ljekovita tvar korisna u liječenju neoplastičnih bolesti i poremećaja imunološkog sustava.
Concentration gave the Intermediate 57 as a white solid (20.20 g, 97%). 
Koncentriranjem je dobiven Intermedijer 57 kao bijela čvrsta supstanca (20.20 g, 97%).
The compound of claim 1, wherein the compound is selected from the groups consisting of the following compounds 
Spoj prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koja se sastoji od slijedećih spojeva
The process of embodiment 6 wherein the isolated fibrids are dried. 
Postupak u skladu s patentnim zahtjevom 6, pri čemu se izolirani fibridi suše.
Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. 
Virus humane imunodeficijencije (HIV) je identificiran kao etiološki čimbenik odgovoran za sindrom stečene imunodeficijencije (SIDA), fatalnu bolest koju karakterizira razaranje imunog sustava i nesposobnost odbijanja opasnih po život oportunističkih infekcija.
A method according to claim 1 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću P1I3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska plućna fibroza (IPF), virusne infekcije dišnog sustava, virusne komplikacije respiratornih bolesti, aspergiloza, lišmenijaza, alergičko rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bolest bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, posthepatična neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
An isolated antibody or antibody fragment thereof that specifically binds to IL-4, wherein the antibody or antibody fragment thereof is humanized and wherein the antibody or antibody fragment thereof comprises a variable light chain comprising the amino acid sequence of SEQ ID NO: 3 and comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 4. 
HR P20180320 T1 PATENTNI ZAHTJEVI Izolirano humanizirano protutijelo ili njegov fragment protutijela koji se specifično veže na IL-13, naznačeno time da protutijelo ili njegov fragment protutijela sadrži varijabilni laki lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 1 i sadrži varijabilni teški lanac koji sadrži sekvencu aminokiseline iz SEQ ID NO: 2.
Item-17) Device according to item 13 wherein the bore egress comprises an intermediate chamber. 
Točka-17) - Uređaj prema točki 13 pri čemu izlazni okvir šupljine ima međukomoru.
receive information associated with transmission of a periodic channel quality indication (CQI) signal in an operating bandwidth, transmit a first acknowledgement signal by using a first frequency resource allocated to the UE, if the UE transmits a dynamic acknowledgement signal in response to reception of a downlink data signal, an resource block (RB) allocated for the first acknowledgement signal being determined based on the received information, and transmit a second acknowledgement signal by using a second frequency resource allocated to the UE, if the UE transmits a periodic acknowledgement signal in response to reception of a downlink data signal, the second frequency resource being allocated between the first frequency resource and a third frequency resource allocated for the periodic CQI signal. 
prijenos indikator kvalitete kanala, CQI, signala uporabom prvog frekvencijskog resursa na svakom kraju operativne pojasne širine, ako KO prenosi CQI signal, i prijenos signala potvrde uporabom drugog frekvencijskog resursa, ako KO prijenosi signal potvrde, naznačeno time da je drugi frekvencijski resurs dodijeljen između prvog frekvencijskog resursa i trećeg frekvencijskog resursa u operativnoj pojasnoj širini, i treći frekvencijski resurs za prijenos uzlazne veze podatkovnog signala je dodijeljen u sredini operativne pojasne širine, pri čemu se CQI signal prenosi periodično, i signal potvrde se prenosi u odgovoru na prijenos silazne veze podatkovnog signala.
The compound or composition of claim 11, wherein the ACE inhibitor is selected from captopril, enalapril, lisinopril, benazepril, quinapril, fosinopril, and ramipril. 
Spoj ili pripravak prema zahtjevu 11, naznačen time da se inhibitor ACE bira iz skupine koju čine kaptopril, enalapril, lizinopril, benazepril, kinapril, fosinopril, te ramipril.
The elastomer material used in the present invention provides the advantage that under irradiation from a focused 980nm laser of power less than 20W, typically 4 - 10 W, e.g. ca. 8 W the thermoplastic elastomer material easily fuses e.g. after ca. 0.5 - 2 seconds, e.g. 1 second maximum irradiation, and sets on cooling without emission of significant quantities of contaminating smoke. 
Elastomerni materijal koji se koristi u predmetnom izumu osigurava prednost da se pod djelovanjem zračenja 980 nm fokusiranog lasera snage manje od 20 W, tipično 4 - 10 W, na primjer, oko 8 W, termoplastični elastomerni materijal lako lijepi, na primjer nakon trajanja zračenja od oko 0.5 - 2 sekunde, na primjer, maksimalno 1 sekunde, i zatim se nastavlja hlađenje bez emitiranja značajnih količina kontaminiranog dima.
Method of manufacturing the extended release tablet formulation according to any of the preceding claims 1 to 6 via a dry granulation process comprising the steps of 
Postupak priprave formulacije tablete produljenog oslobađanja u skladu s jednim od prethodnih zahtjeva 1 do 10, pomoću postupka suhog granuliranja, naznačen time, da sadrži slijedeće korake
CN102558107, Chinese Patent Application Publication No. 
Datum objave europske prijave patenta:
part B which comprises at least 1 B-aggregating region and wherein said region is derived from said protein to be isolated. 
dio B koji sadrži barem jedno B-agregacijsko područje i pri čemu je navedeno područje izvedeno iz navedenog proteina koji treba izolirati.
4 g disclose the blank of the inside front wall 7 in a palette of variations, whereat the inside front wall 7 features side walls 13, an additional upper wall 25, and the bottom wall 26 in different realizations, as well as additional side walls 21 which serve the purpose of joining the vicinal walls. 
4e, SI. 4f1 SI. 4g otkrivaju razne varijante sheme unutarnjeg prednjeg zida 7, a unutarnji prednji zid 7 ima bočne zidove 13, 1 dodatni gornji zid 25, i donji zid 26 u raznim izvedbama, kao i dodatne bočne zidove 21 koji služe za spajanje susjednih zidova.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
An isolated peptide consisting of the amino acid sequence of SEQ ID NO: 30, 19, 22, 34 or 358. 
Peptid u skladu s patentnim zahtjevom 1, naznačen time što se navedeni peptid sastoji od aminokiselinskog slijeda SEQ ID NO: 194, 174, 178 ili 186.
The 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claim 1, wherein Z is CN. 
Derivat 4-fenil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-7, gdje Z je CN.
The laboratory results gave no indications for adverse events or adverse drug reactions. CONCLUSION 
Laboratorijski rezultati nisu dali indikacija za štetne pojave ili štetne reakcije lijeka. ZAKLJUČAK
A polypeptides comprising an amino acid sequence having at least 85%, more preferably at least 90%, even more preferably at least 95%, most preferred 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 4. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu polipeptid ima najmanje 90%, poželjnije 95%, najpoželjnije 99% identičan slijed aminokiselinskom slijedu kako je navedeno u SEQ ID NO-4.
As standard green lumber can be used the output from the highly efficient hardwood lumber industry can be used as raw material vastly increasing the potentially available resource compared to using veneer logs. 
Budući da se mogu koristiti standardne zelene klade, proizvodi iz visoko učinkovite industrije furnira s tvrdim drvom mogu se koristiti kao sirovi materijal, što jako povećava potencijalno raspoložive izvore u usporedbi s korištenjem debla za furnir.
A manipulating inspection device according to any claim 1 to 6, characterized in that the main support (1), the telescopic mast (2), the transverse track (3) as well as the sliding trolley are made of welded sheet metal of a respective length, provided with holes for the purpose of their lightening. 
Manipulacijski inspekcijski uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što su glavni nosač (1), teleskopski jarbol (2), poprečna tračnica (3) kao i klizna kolica načinjeni od zavarenog lima odgovarajuće duljine, koji ima rupe u svrhu njihovog olakšavanja.
The cover panels 6 are mounted to form a formwork or shuttering for the concrete which is then poured in the closed recess so that a column of concrete or other structural fill-material, is formed between the wall elements 2. 
Pokrovne ploče 6 se postavljaju kako bi činile oplatu ili zasun za beton koji se zatim lijeva u zatvorena udubljenja te se tako između zidnih elemenata 2 oblikuje stup od betona ili drugog građevinskog materijala za ispunu.
deficient in proteins involved in DNA DSB repair by HR, wherein the cancer cells optionally are deficient in ATM, Rad51, Rad52, Rad54, Rad50, MRE11, NBS1, XRCC2, XRCC3, cABL, RPA, CtIP and MBC. 
deficitarnih u pogledu proteina uključenih u popravak DBS-a DNK putem HR-a, pri čemu su stanice raka opcionalno deficitarne u pogledu ATMA, Rad51, Rad52, Rad54, Rad50, MREI1, NBS1, XRCC2, XRCC3, CABL, RPA, CtIP i MBC.
A combination in accordance with claim 1 wherein the HMG Co-A reductase inhibitor is selected from lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin. 
Kombinacija koja je u skladu s patentnim zahtjevom 1 gdje je inhibitor HMG-Co-A reduktaze odabran između lovastatina, simvastatina, dihidroksi otvorene kiseline simvastatina, pravastatina, fluvastatina, atorvastatina, pitavastatina i rosuvastatina.
The tablet of embodiment 1 wherein the first layer does not comprise emtricitabine. 
Tableta zahtjeva 1 gdje prvi sloj ne sadrži emtricitabin.
Ring B is wherein R4a is a phenyl group substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkylenedioxy group, an alkyleneoxy group, or a mono- or di-alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxy group or a haloalkoxy group, and R5a is a hydrogen atom; 
S. _R rI Sa R gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom, halogenalkoksi skupinom, alkilendioksi skupinom, alkilenoksi skupinom ili mono- ili di-alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, alkilnom skupinom, halogenalkilnom skupinom, alkoksi skupinom ili halogenalkoksi skupinom; a R* je atom vodika;
about 1 to about 4 pH units below the pI of the monoclonal antibody; 
oko 1 do oko 4 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela;
1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), characterized by at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response that the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections. 
1 ili njegov fragment koji obuhvaća barem aminokiselinske ostatke 221 do 531 regije koja veže fibrinogen (Regija A), naznačeno barem jednom supstitucijom ili delecijom aminokiselinskog ostatka na aminokiselinskom ostatku Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 i/ili Val527 da se dobije rekombinantni fibrinogen vezujući protein sa smanjenom sposobnosti ili bez sposobnosti nekovalentnog vezanja fibrinogena što će stimulirati veći imuni odgovor od divljeg tipa CIfA proteina, za uporabu u liječenju ili prevenciji stafilokoknih infekcija.
The liquefied gas treatment system according to claim 1, wherein the BOG, which is liquefied by the heat exchanger (21) and decompressed by the decompressing means (22), is returned to the cargo tank (1;11). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
Another object of the present invention is to provide such a core for rolls of sheet material that is compatible with the web of the roll and at the same time recyclable. 
Drugi predmet ovog izuma sastoji se u stvaranju jezgre za svitke laminata podobne s namotanim materijalom, a koja se istodobno može i reciklirati.
The method according to claim 1, said method comprising the administration of said FGF-18 compound at a dose of about 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mcg per single intra-articular administration. 
Spoj FGF-18 za uporabu prema zahtjevu 7, naznačen time da se spoj FGF-18 daje u dozi od oko 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 mcg po jednom intra-artikularnom davanju spoja FGF-18.
the variable region of the heavy chain comprises: 
Broj objave europskog patenta:
Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. 
Drugi način za otapanje racemata u optičke antipode temelji se na kromatografiji na optički aktivnoj matrici.